All News
Filter News
Found 808,462 articles
-
Impel NeuroPharma Announces Key Management Team Appointments As Company Advances Toward Commercialization In 2021
3/1/2021
Impel NeuroPharma, a late-stage pharmaceutical company focused on utilizing our proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, today announced the appointments of Leonard S. Paolillo as chief commercial officer and Gerald F. Penn as vice president, market access and trade
-
MannKind Corporation Announces Proposed Private Placement of Convertible Senior Notes
3/1/2021
MannKind Corporation announced that it intends to offer, subject to market conditions and other factors, $150.0 million aggregate principal amount of Convertible Senior Notes due 2026 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
-
Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia
3/1/2021
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ARO-APOC3, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with hypertriglyceridemia.
-
Apollo Endosurgery Receives FDA Breakthrough Device Designation for the Orbera(R) Intragastric Balloon for Treatment of Patients with NASH
3/1/2021
Apollo Endosurgery, Inc. announced that it has received a Breakthrough Device Designation from the U.S. Food and Drug Administration for the Orbera® Intragastric Balloon, specifically for the indication for use in treating patients with BMI between 30-40 kg/m2 with noncirrhotic nonalcoholic steatohepatitis with liver fibrosis.
-
Intellipharmaceutics Announces Fiscal Year 2020 Results
3/1/2021
Intellipharmaceutics International Inc. and, a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, reported the results of operations for the year ended November 30, 2020.
-
BioSkryb Announces the Winners of Its Grant Program to Aid Research Using Primary Template-directed Amplification Technology
3/1/2021
Today, at the Advances in Genome Biology and Technology (AGBT) 2021 General Meeting held virtually, BioSkryb, Inc., a developer of genomic amplification technologies, announced the winners of a research grant program sponsored by the company.
-
9 Meters Biopharma, Inc. Appoints Michael Rice to Board of Directors
3/1/2021
9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today the Company has appointed Michael Rice to its board of directors.
-
Cyclo Therapeutics Appoints Gerald F. Cox, MD, PhD as Acting Chief Medical Officer
3/1/2021
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company developing cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer’s Disease, today announced the appointment of Gerald F. Cox, MD, PhD as Acting Chief Medical Officer.
-
Amicus Therapeutics Announces Full-Year 2020 Financial Results and Corporate Updates
3/1/2021
Amicus Therapeutics, a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, announced financial results for the full year ended December 31, 2020.
-
XWPharma Names Glen Giovannetti to Board of Directors
3/1/2021
New Board Member Brings Extensive Experience in Financial Oversight and Governance in the Life Sciences Industry as Company Advances its Pipeline of Novel CNS Therapeutics, Preparing for Future Stages of Growth and Development
-
GRAM Applauds FDA Emergency Use Authorization for Johnson & Johnson COVID-19 Vaccine
3/1/2021
Grand River Aseptic Manufacturing ("GRAM"), a leading parenteral contract development and manufacturing organization ("CDMO"), congratulates Johnson & Johnson on receiving emergency use authorization from the Food and Drug Administration ("FDA") for its single-shot COVID-19 vaccine
-
4D Pharma Appoints John Beck as Chief Financial Officer and Member of the Management Team
3/1/2021
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces the appointment of John Beck as Chief Financial Officer (CFO) and member of the Company’s management team
-
Bracco and the Society for Advanced Body Imaging (SABI) Announce Partnership in Launch of the New SABI Bracco Mentorship Program
3/1/2021
Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, and the Society for Advanced Body Imaging announced the launch of the new SABI Bracco Mentorship Program, which aims to support the academic and professional development of SABI members throughout their careers.
-
CorMedix Receives Complete Response Letter From FDA for DefenCath™ Catheter Lock Solution
3/1/2021
CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that the US Food and Drug Administration (FDA) cannot approve the New Drug Application (NDA) for DefenCath™ (taurolidine/heparin catheter lock solution) in its present form
-
Satsuma Pharmaceuticals Announces $80 Million Private Placement Financing
3/1/2021
Satsuma Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company, announced that it has agreed to sell 14,084,507 shares of its common stock to certain institutional investors in a private investment in public equity financing.
-
STRATA Skin Sciences Announces CEO Transition
3/1/2021
STRATA Skin Sciences, Inc., a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced Robert Moccia has been appointed President and Chief Executive Officer and a member of the board, effective March 1, 2021.
-
Coronavirus (COVID-19) Update: FDA Issues Authorization for Quidel QuickVue At-Home COVID-19 Test
3/1/2021
Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the Quidel QuickVue At-Home COVID-19 Test, another antigen test where certain individuals can rapidly collect and test their sample at home, without needing to send a sample to a laboratory for analysis.
-
4D Pharma Appointments Paul Maier to the Board as Non-Executive Director
3/1/2021
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces the appointment of Paul Maier as Non-Executive Director of the Board. Mr Maier will also be a member of 4D's Audit and Risk Committee and will serve as the Company’s “audit committee financial expert"
-
Trevena, Inc. to Participate in March 2021 Virtual Investor Conferences
3/1/2021
Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced that management will participate in two upcoming virtual investor conferences in March.
-
Arvinas Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
3/1/2021
Arvinas, Inc., a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update.